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Quantitating the epigenetic transformation
contributing to cholesterol homeostasis using
Gaussian process
Chao Wang 1, Samantha M. Scott1, Kanagaraj Subramanian1, Salvatore Loguercio 1, Pei Zhao1,
Darren M. Hutt1, Nicole Y. Farhat2, Forbes D. Porter2 & William E. Balch 1*
To understand the impact of epigenetics on human misfolding disease, we apply Gaussian-
process regression (GPR) based machine learning (ML) (GPR-ML) through variation spatial
profiling (VSP). VSP generates population-based matrices describing the spatial covariance
(SCV) relationships that link genetic diversity to fitness of the individual in response to
histone deacetylases inhibitors (HDACi). Niemann-Pick C1 (NPC1) is a Mendelian disorder
caused by >300 variants in the NPC1 gene that disrupt cholesterol homeostasis leading to the
rapid onset and progression of neurodegenerative disease. We determine the sequence-to-
function-to-structure relationships of the NPC1 polypeptide fold required for membrane
trafficking and generation of a tunnel that mediates cholesterol flux in late endosomal/
lysosomal (LE/Ly) compartments. HDACi treatment reveals unanticipated epigenomic
plasticity in SCV relationships that restore NPC1 functionality. GPR-ML based matrices
capture the epigenetic processes impacting information flow through central dogma, pro-
viding a framework for quantifying the effect of the environment on the healthspan of the
individual.
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A major challenge in the genomic era is to understand theimpact of genetic and epigenetic diversity on the proteinfold and its function in biology in response to the envir-
onment1–4. Lysine (Lys) acetylation/deacetylation balance, which
is catalyzed by writers (histone acetyltransferases (HATs)) and
erasers (histone deacetylases (HDACs)), manage epigenetic
information to harmonize numerous cellular processes through
readers (acetyl-binding proteins)5. Given the strong links to
development, metabolism and aging, Lys acetylation/deacetyla-
tion has been considered an important epigenetic mechanism that
uses cellular and environmental cues to specialize individual
phenotypes in response to their unique genomic and environ-
ment exposure5–8. How the acetylation/deacetylation balance
managed by HDAC coordinates the phenotype of genetic varia-
tion programmed by central dogma that is responsible for fitness
in health and disease is largely unknown.
To generate a more complete understanding of the impact of
HDAC on genetic variation in the population and its impact on
the individual, we apply variation spatial profiling (VSP)1 to
understand the process triggering onset and progression of
Niemann-Pick C1 (NPC1) disease, an early onset neurodegen-
erative disease caused by accumulation of unesterified cholesterol
in the late endosome/lysosome (LE/Ly) compartments of all cells.
VSP is a Gaussian-process regression (GPR)-based machine-
learning (ML) (GPR-ML) approach9,10 we have recently devel-
oped to characterize spatial covariance (SCV) relationships that
predict the genomic-phenomic transformation in the individual
in response to genetic diversity in the extant population1,3,11. VSP
emphasizes sequence-to-function as a prior to structure as it is
function that dictates the process of fitness in evolability in
response to the local genetic, biologic and physical environment1.
Using our VSP strategy to define the impact of HDAC on
Niemann-Pick C1 variants found in the world-wide population
that disrupt cholesterol homeostasis, we show on a residue-by-
residue basis that epigenetic-sensitive SCV relationships in the
protein fold can be retuned by HDACi to coordinate protein
trafficking with the flow of cholesterol in the LE/Ly. Restoring
plasticity to the fold design disrupted by variation in the popu-
lation we predict will delay the age of neurological disease onset.
Our results highlight the power of GPR-ML to quantitatively
capture the role of HDAC biology in acetylation balance to
improve fitness using a SCV matrix based definition of central
dogma (SCV[DNA|RNA|Protein])1.
Results
NPC1 variant impact on trafficking and cholesterol. To char-
acterize the process by which HDACs impact genetic variation in
the human population using GPR- ML1, we focused on the rare
autosomal recessive childhood disease, Niemann-Pick type C
(NPC). NPC disease is triggered by familial genetic diversity
within the NPC1 gene (95% of patients) through >300 disease
variants12,13. Defects in NPC1 function lead to abnormal accu-
mulation of cholesterol and other lipids in the LE/Ly in all cell
types, although typically manifested in clinical presentation as
neurodegeneration where the age of onset and severity of disease
is unique for each patient genotype13–17. NPC1 encodes a multi-
membrane spanning protein (Fig. 1a) that is translocated and
folded in the endoplasmic reticulum (ER) and trafficked through
the Golgi to late endosome (LE)/lysosome (Ly) (LE/Ly) com-
partments where it manages cellular cholesterol homeostasis18,19.
Immunoblot analysis of patient-derived NPC1 primary fibro-
blasts harboring different alleles shows substantial heterogeneity
in both polypeptide expression and stability compared with
fibroblasts expressing the wild-type (WT) NPC1 (Supplementary
Fig. 1, Supplementary Table 1).
NPC1 acquires up to 14 N-linked glycans during co-
translational translocation into the ER. These ER-localized high
mannose glycoforms are sensitive to digestion by endoglycosidase
(Endo) H (Endo HS) in cell lysates prepared by detergent
solubilization. Following delivery from the ER to the Golgi, the N-
linked glycans are progressively processed to Endo H resistant
(Endo HR) glycoforms by the Golgi, leading to slower migration
on SDS-PAGE. In primary fibroblasts (Fig. 1b), the WT-NPC1
glycoform was highly resistant to Endo H digestion, indicating
efficient transfer to the Golgi whereas heterozygous alleles and the
common I1061T homozygous variant fibroblast populations20
showed differential sensitivity to Endo H with I1061T being
restricted to the ER (Fig. 1b). To characterize the impact of each
allele on NPC1 features, we silenced NPC1 expression with
shRNA to generate stable Hela and U2OS null cell lines21. These
null cell lines were transiently transfected with a sparse collection
of plasmids that each harbors one of 48 distinct NPC1 disease-
associated variants distributed among the various NPC1 domains
(Fig. 1c, Supplementary Fig. 2)21.
To follow trafficking from the ER, we measured the level of
Endo HS and Endo HR glycoforms for each variant and generated
an Endo HR/(Endo HS+ Endo HR) ratio that reports on the ER
versus post-ER distribution of NPC1 variants in the cell, referred
to hereafter as the trafficking index (TrIdx)1. We binned this
sparse collection of variants into four functional classes (classes
I–IV) based on TrIdx (Fig. 1d, left panel, black circles;
Supplementary Table 2, Source data are provided as a Source
Data file). Class I variants lack polypeptide expression in response
to non-sense or splicing (truncation) mutations (null) (Supple-
mentary Table 2); class II missense variants are largely ER
retained (defined as ~< 0.2 TrIdx); class III missense variants
show an intermediate level of trafficking (defined as ~0.2 to ~0.5
TrIdx); and class IV missense variants have a level of TrIdx ~> 0.5
indicating significant export from the ER (Fig. 1d, left panel;
Supplementary Table 2). The distribution of TrIdx of each variant
in the two cell lines tested were largely consistent (Supplementary
Fig. 3, Pearson’s r= 0.55; p-value= 1 × 10−4 (ANOVA test)) with
the exceptions where select class II variants in Hela cells are
scored as class III in U2OS cells reflecting increased flow from the
ER (Supplementary Fig. 3, Supplementary Table 2). Comparison
of the two developmentally distinct cell-based lineages suggests a
remarkable general conservation of NPC1 variant trafficking
through the endomembrane system to the LE/Ly (Supplementary
Fig. 3).
The impact of cholesterol (Chol) storage in the LE/Ly for each
of these variants was measured using a well-established
automated high content screening image analysis based on filipin
staining in the U2OS cell line21,22 (Fig. 1d, right panel, black
circles). The combined results revealed a gradient of cholesterol
accumulation in the LE/Ly compartments reflecting the differ-
ential impact of a specific variant on trafficking and/or function
in the LE/Ly (Fig. 1d, black circles)21. Because each of the 48
variants tested contribute to clinical disease, these results suggest
that either nascent synthesis, ER stability, trafficking from the ER
or function in LE/Ly can differentially contribute to clinical
presentation of disease.
Impact of SAHA on trafficking and cholesterol. The FDA-
approved histone deacetylase inhibitors (HDACi) Vorinostat
(SAHA) and Panobinostat (LBH589) can correct the I1061T
phenotype in cell-based models by stabilizing the I1061T protein
for export to the LE/Ly where it contributes to improved cho-
lesterol homeostasis21,23,24. Each of the 48 NPC1 variants were
examined for the impact of SAHA on Chol in the LE/Ly in the
U2OS cell line to that of trafficking in the Hela cell line given the
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Fig. 1 Response of NPC1 variants to SAHA. a Schematic representation of domains in NPC1 (sterol-binding luminal N-terminal domain 1 (SNLD1), N-
terminal transmembrane domain 2 (NTMD2), middle luminal domain 3 (MLD3), sterol-sensing transmembrane domain 4 (STMD4), C-terminal luminal
domain 5 (CLD5), C-terminal transmembrane domain 6 (CTMD6)). b (Upper panel) Trafficking of NPC1 variants from the ER (Endo H sensitive (Endo HS))
to post-ER LE/LY compartments (Endo H resistant (Endo HR)) glycoforms in wild-type (WT) and NPC1 patient fibroblasts. (Bottom panel) Fraction of total
of NPC1 in Endo HR (black) and Endo HS (white) glycoforms (mean ± s.d.). c NPC1 variants are mapped as balls on the C-alpha position in the
NPC1 structure25,29. The cholesterol molecule is shown in magenta25,35. d (Left panel) Trafficking index (TrIdx) of 48 NPC1 variants in the absence (black
circles as control (CTL)) or presence of SAHA (red squares). WT, I1061T variants are indicated by vertical dash lines and trafficking classes (II, III, IV) by
horizontal dash lines. (Right panel) Cholesterol (Chol) homeostasis of 48 NPC1 variants in the absence (black circles as control (CTL)) or presence of
SAHA (red squares for p-value < 0.05; blue squares for p-value > 0.05; student’s two tailed t-test)21. WT and I1061T variants are indicated by vertical dash
lines. Chol of WT in the absence or presence of SAHA highlighted by horizontal dashed lines. Data are presented as mean ± s.e.m.21 (Source data are
provided as a Source Data file). e Domain specific response to SAHA. NPC1 variants are clustered into different domains for TrIdx (left panel) and Chol
(right panel) comparison (box and whisker plot: box= 25th and 75th, whiskers extend from minimum to maximum of the data; p-value (Student’s two
tailed t-test)). f Correlation between TrIdx and Chol of NPC1 variants in the absence (left panel) or presence (right panel) of SAHA. Pearson’s r and the p-
value (ANOVA test) with null hypothesis as the coefficient equal to zero is indicated. g Redistribution of different trafficking classes in response to SAHA.
The percentage of variants in different classes in absence (f, left panel) or presence (f, right panel) of SAHA is shown
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larger differential of trafficking features captured for each variant
(Fig. 1d; Supplementary Fig. 3; Supplementary Table 2). Similar
to NPC1-I1061T fibroblasts20,21,23, the majority of NPC1 variants
with a TrIdx <0.2 (Fig. 1d, left panel, class II) were corrected by
SAHA to at least a class III TrIdx, while variants with >0.2 TrIdx
(Fig. 1d, left panel, classes III and IV) showed a more variable
impact of SAHA on TrIdx. In contrast, HDACi improved Chol
homeostasis for most variants to a level comparable to or greater
than that observed in either untreated or SAHA-treated WT-
NPC1 cells (Fig. 1d, right panel), a result similar to that observed
for LBH589, a HDACi previously shown to correct I1061T at nM
concentrations21 (Supplementary Fig. 4a). The effects of HDACi
were NPC1-dependent as restoration of Chol homeostasis by
SAHA was not observed in fibroblasts lacking NPC123 and in null
cell lines lacking NPC121.
NPC1 contains three luminal domains (SNLD1, MLD3, and
CLD5) and three transmembrane domains (NTMD2, STMD4, and
CTMD6) with 13 transmembrane helices (TM 1–13) (Fig. 1a)25–29.
When we grouped variants by structural domains (Fig. 1a, c), both
the luminal MLD3 and CLD5 variants that have relatively low
TrIdx values showed a statistically significant correction of TrIdx in
their response to SAHA compared with all other domains (Fig. 1e,
left panel). In contrast, cholesterol homeostasis was significantly
restored by either SAHA (Fig. 1e, right panel) or LBH589
(Supplementary Fig. 4b, c)21 for variants in all domains. While
Chol homeostasis of NPC1 variants in the vehicle control showed a
modest but significant correlation with TrIdx (Fig. 1f, left panel,
Pearson’s r-value=−0.36, p-value= 0.01 (ANOVA test)), SAHA
eliminated this correlation by shifting most variants to a class III
phenotype (Fig. 1f, right panel, Pearson’s r-value=−0.07, p-value
= 0.64 (ANOVA test), Fig. 1g). Moreover, the correlation between
the delta (Δ) of Chol and Δ of Trldx in the absence or presence of
SAHA, or the Δ of Chol and the Δ of the mature NPC1 glycoform,
indicating delivery to the Golgi in response to SAHA, were not
statistically significant (Supplementary Fig. 5). These results suggest
that SAHA differentially impacts the management of variants
contributing to ER export and those contributing to cholesterol
homeostasis in the LE/Ly, illustrating that the HDACi modified
environment can significantly and differentially contribute to
variant functionality.
VSP analysis of NPC1 variants. To understand in depth the
complex genotype to phenotype transformation process respon-
sible for NPC1 disease in response to HDACi reported by NPC1
variants, we applied variation spatial profiling (VSP) to quantitate
the spatial covariance (SCV) of sequence-to-function-to-structure
relationships1 for the entire NPC1 polypeptide in the absence or
presence of HDACi. VSP uses sparse known variants and their
related functional features in the population to predict a quan-
titative function value (referred to as a SCV set-point) for each
residue in the polypeptide chain. These set-point values are
associated with an uncertainty that assigns the SCV tolerance for
all known and unknown variants in predicting any functional
feature1,11. The combined known and predicted unknown values
constitute a phenotype landscape that provides a quantitative
interpretation of covarying sequence-to-function-to-structure
relationships across the entire NPC1 fold, in this case the impact
of epigenetics on the functional rescue of NPC1 variant
by HDACi.
To build phenotype landscapes1, the x-axis is the normalized
linear position of each of the 48 variant in the NPC1 polypeptide
sequence (referred to as VarSeqP) that provides spatial informa-
tion across the entire primary sequence as would be normally
assigned by transcription and translation machineries (Fig. 2a).
To assign the relationship of each genotype to a function, the y-
axis input was set as the known value of each variant’s Chol
measurement (Fig. 2a). To address the impact of VarSeqP-to-
Chol relationships on the TrIdx, given the spatial importance of
cellular location in proper management of cholesterol by NPC1 in
LE/Ly18,30–32, an input z-value was set as the known TrIdx value
for each variant (Fig. 2a, z-axis, colored gradient). The spatial
relationships defined by the x-axis genotype and functional y- and
z-axes coordinates provide a quantitative framework to under-
stand the transformation from the linear genotype to phenotype
reflected in function based on the choice of y- and z-axis
coordinates1.
To assess the SCV relationships for all possible 1128 pairwise
combinations of known variants (Fig. 2a), a molecular variogram1
is computed (Fig. 2b, Supplementary Fig. 6a). Here, the molecular
variogram shows that the spatial variance of TrIdx in the absence
of SAHA (Fig. 2b, black line, y-axis) increases according to
VarSeqP-to-Chol distances (Fig. 2b, x-axis), referred to as the
range1 (Fig. 2b, x-axis position 0.19, vertical dashed black line),
until it reaches a plateau (Fig. 2b, y-axis position 0.05, horizontal
black line). A range of 0.19 suggests that the TrIdx and Chol
function of variants are generally dependent on each other only
over a short sequence range of ~250 amino acids (Fig. 2b, x-axis)1,
indicating a SCV modular design of the NPC1 polypeptide
sequence that relates genotype to the different phenotypes
contributing to trafficking and cholesterol management. Strikingly,
SAHA significantly reduced the range shown on the x-axis (Fig. 2b,
red line SAHA, range value 0.03 (~40 amino acids)). Moreover, the
spatial variance on the y-axis defines a plateau which describes the
stringency of the fold1. Here, the plateau of the spatial variance for
TrIdx is reduced by ~40% in response to SAHA (Fig. 2b; compare
horizontal black line vehicle control (control (CTL), plateau=
0.05) to the horizontal red line in the presence of SAHA (plateau
= 0.03); Supplementary Fig. 6a, p-value= 7 × 10−23 (student’s t-
test)). Thus, the plateau spatial variance defined by the molecular
variogram suggests that HDACi increases the set-point tolerance of
each known variant residue interaction leading to increased
plasticity in TrIdx. The outcome is to reduce the loss-of-function
impact of the variants, resulting in an improvement in cholesterol
homeostasis for most of the disruptive variant features.
Phenotype landscapes predict the TrIdx-functional structure.
To expand the spatial relationships modeled by the molecular
variogram with known variants (Fig. 2b) to all other unknown
residues, we apply GPR-ML1 to generate an output TrIdx-
phenotype landscape (Fig. 2c). The Trldx-phenotype landscape
quantitates all SCV relationships between the known and the
unknown (predicted) TrIdx values (z-axis) for each amino acid
residue in NPC1 polypeptide chain in response to the VarSeqP
(x-axis) and Chol (y-axis) coordinates relationships, thereby
linking sequence position to cellular location to cholesterol-
related function of NPC1 (Fig. 2c). GPR-ML not only generates
set-point predictions on a residue-by-residue basis but also
assesses the uncertainty of the prediction (Supplementary Fig. 6b)
(i.e., SCV tolerance of each set-point), of which the leave-one-out
cross-validation achieves a more accurate prediction than mul-
tivariate linear regression or decision tree-based regression
methods (Supplementary Fig. 6c–e). The uncertainty (or con-
fidence) in using SCV relationships for prediction is defined by
contour maps that are embedded in the phenotype landscape
(Fig. 2c, Supplementary Fig. 6b) that show the strength of all SCV
relationships found in the range of the molecular variogram
(Fig. 2b)1. The TrIdx-phenotype landscape (Fig. 2c, left) reveals
diverse trafficking values where variants with defective trafficking
of high confidence are mainly localized in the luminal MLD3 and
CLD5 domains (Fig. 2c, left; SCV clusters 1 and 2), indicating that
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Fig. 2 TrIdx-phenotype landscape and TrIdx-structure in the absence and presence of SAHA. a NPC1 variants are positioned by their variant sequence
position (VarSeqP) (x-axis) normalized to the full-length sequence and measured Chol values of NPC1 variants (y-axis normalized to I1061T) in the
absence (left panel) or presence (right panel) of SAHA. The projected z-axis (color gradient) is defined by the absolute measured TrIdx of each variant.
The spatial relationships of pairwise comparisons of variants are illustrated as black lines. b The molecular variogram illustrating the spatial variance of
measured TrIdx for distance values defined by VarSeqP and Chol in the absence (black line) or presence (red line) of SAHA (see Methods; Supplementary
Fig. 6a). c VSP predicted TrIdx-phenotype landscape is shown as a heatmap in the absence (left panel) or presence (right panel) of SAHA. Confidence
relationships (see Supplementary Fig. 6b) within the molecular variogram range are plotted as contour lines and the top 25% confidence quartile is shown
as a bold line. Color-scale values: defective trafficking (red); ~50% WT trafficking (yellow); WT trafficking (green). I1061T ER-restricted variant is bolded.
Dashed ovals 1 and 2 highlight two SCV clusters found in the top 25% confidence quartiles that have defective trafficking in the absence of SAHA.
d Mapping the TrIdx-phenotype landscape on the NPC1 structure25,29. The highest confident prediction of the TrIdx value and the corresponding Chol
value is assigned for each residue with ball color representing TrIdx, ball size representing Chol, and transparency representing prediction confidence. SCV
cluster 1 and 2 are selectively highlighted as balls in cartoon presentation of the structure
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these sequence regions are critical for export from the ER based
on poor acquisition of Endo HR glycoforms. Furthermore, TrIdx-
phenotype landscapes based on input data from U2OS cells reveal
similar regions critical for trafficking (Supplementary Fig. 6g),
indicating the conserved role of MLD3 and CLD5 mediating
NPC1 trafficking across different cell lines.
Strikingly, the TrIdx-phenotype landscape (Fig. 2c, left panel)
undergoes a general compression in the presence of SAHA
(Fig. 2c, right panel). These results reveal that the global
improvement in cholesterol homeostasis in response to HDACi
(Fig. 2c, y-axis) occurs, in part, through new SCV relationships
that convert poor class II TrIdx values (Fig. 2c, left panel, orange-
red) to improved class III TrIdx values (Fig. 2c, right panel,
yellow). For example, SCV cluster 2 in CLD5 (Fig. 2c, left panel,
dashed oval 2), that has a severe defect for both TrIdx and Chol,
undergoes a coordinated shift towards WT-like Chol function (y-
axis) and a class III TrIdx (z-axis) (Fig. 2c, right panel, dashed
oval 2) as highlighted in a 3D projection of the TrIdx-phenotype
landscape (Supplementary Fig. 6f, cluster 2). In contrast in SCV
cluster 1, the lack of significant correction of Chol of H510P21 is
due to the inability of SAHA to improve its TrIdx (Fig. 2c,
Supplemental Fig. 6f). Moreover, the large improvement of the
TrIdx of R518Q set-point does not significantly improve
cholesterol homeostasis reflecting the critical role of this residue
in binding of NPC2 for cholesterol transfer (Fig. 2c, Supplemen-
tary Fig. 6f)21.
VSP generated TrIdx-phenotype landscapes (Fig. 2c) can be
directly mapped onto the NPC1 structure25,27,29 to generate a
functional structure1 that enables function assignment of each
amino acid residue in a structure snapshot (Fig. 2d). The
functional structure reveals the overlapping and/or distinct
contribution of all the NPC1 residues to trafficking (Fig. 2d, ball
color) and cholesterol homeostasis (Fig. 2d, ball size) with a
prediction confidence (Fig. 2d, ball transparency)1. Strikingly, the
TrIdx-functional structure reveals a molecular handshake
between MLD3 and CLD5 (Fig. 2d, CTL panel, clusters 1 and
2) as a central feature that determines the ER export of NPC1 in
Hela (Fig. 2d, CTL panel, red residues) and U2OS cell lines
(Supplementary Fig. 6h) from the ER. Moreover, atomic
resolution mapping of the impact of SAHA on the functional
structure reveals a significant improvement in cholesterol home-
ostasis for nearly all residues (Fig. 2d, SAHA panel, increased of
ball size), partially by shifting the class II TrIdx (Fig. 2d, CTL
panel, red balls) to that of class III indicative of significant export
from the ER (Fig. 2d, SAHA panel, orange and yellow balls).
Thus, the phenotype landscape predicted from the collective of
fiduciary NPC1 variants found in the world-wide patient
population using VSP teach us about the SCV modules and
their function linked structural features required for normal
NPC1 trafficking.
Phenotype landscapes predict the Chol-functional structure. To
assign a value to cholesterol homeostasis based on the TrIdx
response to NPC1 variants, we flipped the biological features used
for y-axis and z-axis (Fig. 3a, Supplementary Fig. 7). The mole-
cular variogram modeling of these relationships in the absence of
SAHA shows that the spatial variance of Chol (Fig. 3b, y-axis)
increases according to the distance defined by the VarSeqP-to-
TrIdx spatial relationship (Fig. 3b, x-axis), revealing a range ~0.08
(Fig. 3b, black vertical dash line). A range of ~0.08 suggests that
the spatial variance of cholesterol homeostasis (Fig. 3b, black line,
y-axis) is dependent on VarSeqP-to-TrIdx over a sequence range
of ~100 amino acids (Fig. 3b, black line, x-axis). Strikingly, SAHA
decreases the range from 0.08 to 0.02 and significantly reduces the
spatial variance of the Chol value by nearly 70% (Fig. 3b; compare
black line plateau= 0.02 with red line plateau= 0.005; Supple-
mentary Fig. 7a, p-value= 5 × 10−79 (student’s t-test)). The
decreased Chol spatial variance of NPC1 variants in response to
SAHA (Fig. 3b, 70%) is significantly larger than the decrease
observed for TrIdx spatial variance (Fig. 2b, 40%), indicating that
SAHA correction in post-ER LE/Ly acidic compartments
increases the overall SCV plasticity1 of the variant fold to improve
function to facilitate Chol homeostasis.
We next generated an output Chol-phenotype landscape that
predicts cholesterol responses across the entire polypeptide
sequence in the context of all VarSeqP-TrIdx spatial relationships
(Fig. 3c, Supplementary Fig. 7b–e). Interestingly, the Chol-
phenotype landscape in the absence of SAHA reveals two SCV
clusters in the top 25% confidence quartile that show class III
TrIdx yet have severe cholesterol homeostasis defects (Fig. 3c, left,
dashed ovals). One cluster is found in STMD4 (cluster 3) and the
other spanning CLD5 and CTMD6 (cluster 4) (Fig. 3c, left panel).
These SCV relationships suggest that clusters 3 and 4 are critical
in mediating cholesterol management in the LE/Ly. Indeed, P691
in SCV cluster 3 has been shown to be involved in cholesterol
binding26,27,33,34. Thus, the Chol-phenotype landscape reveals
that regions in CLD5, CTMD6 and STMD4 contribute together
to tune cholesterol flow (Fig. 3c, left panel).
The Chol-phenotype landscape (Fig. 3c, left panel) undergoes a
striking change in the presence of SAHA (Fig. 3c, right panel)
highlighting the ability of SAHA to improve cholesterol home-
ostasis for most of variants (Fig. 3c, red-orange in the left panel
shifts to cyan and blue in the right panel). Moreover, the high
confidence region (Fig. 3c, left panel, 25%; right panel, 5%,
respectively) defined by the range in the molecular variogram
(Fig. 3b) are decreased substantially by SAHA indicating a loss
of spatial interdependency of variant residues triggering disease.
The correction of cholesterol homeostasis (z-axis) of variants
found in the regions defined by SCV clusters 3 and 4 even in the
absence of improvement of their TrIdx (y-axis) indicates that
SAHA can independently adjust the function of NPC1 in the LE/
Ly to improve cholesterol homeostasis (Fig. 3c, Supplementary
Fig. 7f)21.
By projecting Chol-phenotype landscape at atomic resolution
onto the structure of NPC1, the variation seen in the NPC1
population can now be used to map a potential path of cholesterol
flow in NPC1 (Fig. 3d, e). Based on class III variants (Fig. 3d, CTL
panel, medium size balls) that are primarily defective in
cholesterol homeostasis (Fig. 3d, CTL panel, orange-red balls),
the Chol-functional structure reveals (Fig. 3d, CTL panel) the
critical residues for cholesterol export that include SCV cluster 4
residues in CLD5 and CTMD6, as well as SCV cluster 3 residues
in STMD4, the later recently proposed to form a second
cholesterol binding site27. Moreover, the proline-rich linker
between SNLD1 and the TM region that has been suggested to
facilitate cholesterol transfer35 is now shown by SCV analysis to
have little impact on trafficking yet contribute to the flow of
cholesterol in NPC1 (Fig. 3d, CTL panel). The structural mapping
of Chol-phenotype landscapes based on trafficking values from
the Hela and U2OS cell lines yields similar pattern (Supplemen-
tary Fig. 7g, h), indicating VSP is able to capture a common
phenotypic feature using different cell and tissues harboring
variant genotypes1, suggesting that these are conserved genetic
and epigenetic relationships. Based on our SCV analyses, a
potential cholesterol flow path is highlighted in the TM region
(Fig. 3e). The SCV relationships of variants found along the flow
path lead to improved cholesterol homeostasis in response to
SAHA (Fig. 3e, SAHA panel, green-cyan-blue), suggesting a role
for CLD5 and CTMD6 in export of cholesterol from the LE/Ly by
increasing NPC1 plasticity (i.e., a decrease in the SCV
dependence) (Fig. 3b).
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HDACi responsive delta (Δ)-functional structures. Given the
differences in the basal and HDACi condition (Figs. 2 and 3), we
can generate functional structures that directly capture the delta
(Δ) values from TrIdx and Chol-phenotype landscapes. The Δ
TrIdx structural state (Fig. 4a, b) highlights that the trafficking
properties conferred by MLD3 and CLD5 residues are corrected
by SAHA (Fig. 4a, cyan to blue). In contrast, SNLD1 is largely
resistant to SAHA (Fig. 4a, yellow to red in left panel; gray in
right panel). The TM region is also largely resistant to SAHA
(Fig. 4a, yellow to red in left panel; gray in right panel) as the
trafficking of the variants involved in the predicted path of cho-
lesterol flow are not changed by SAHA (Fig. 4b, yellow balls). In
contrast to the Δ TrIdx-functional structures, the Δ Chol-
functional structure highlights the fact that the residues dis-
tributed throughout the polypeptide chain can participate in the
response of NPC1 to SAHA (Fig. 4c, cyan to blue). These changes
are particularly evident in residues involved in the predicted path
of cholesterol flow (Fig. 4d). The dramatic improvement of
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cholesterol homeostasis for TM3-4 in STMD4 and TM9-13 in
CTMD6 (Fig. 4d, cyan and blue regions) is achieved without
significant improvement of TrIdx (Fig. 4b, yellow regions),
indicating that the dynamics of these TM helices in response to
SAHA contribute uniquely to the flow of cholesterol in the LE/Ly.
Mechanism of action of SAHA. HDACi have been shown to
modulate the post-translational acetylation state of numerous
cellular proteins5,8,36, thereby altering their functional states
impacting many cellular pathways including altered stability and
targeting for degradation21,24,37–40. To examine the impact of
HDACi on the acetylation of NPC1, we immunoprecipitated
cellular acetylated proteins with an acetylated-lysine (AcK) anti-
body in the absence or presence of SAHA and probed for the
presence of acetylated NPC1. Intriguingly, SAHA promoted
hyperacetylation for both WT-NPC1 and I1061T-NPC1 (Fig. 5a),
consistent with our recent observations that hyperacetylation of
I1061T-NPC1 variant by treatment with the low affinity (mM)
HDACi valproic acid (VPA), that targets similar Zn+2-dependent
HDACs to SAHA, prevents the proteosomal degradation of
I1061T-NPC141. To explore this result, we analyzed the heat
shock response (HSR) pathway42,43, under the control of the heat
shock factor 1 (Hsf1) transcription factor. We have previously
shown that the chronic expression of misfolded proteins, such as
I1061T-NPC1, results in the sustained activation of the HSR
termed the maladaptive stress response (MSR)44, and that silen-
cing Hsf1 promotes the stability and trafficking of I1061T-
NPC144. We observed that SAHA induced a significant reduction
in the level of both Hsf1 and Hsf1-P (Fig. 5b) indicating a reduced
MSR. Furthermore, the cellular expression of BAGs 1–3,
nucleotide exchange factors regulating the activity of heat shock
protein 70 (Hsp70) induced by HSR are also significantly reduced
by SAHA (Fig. 5b). These results are consistent with the obser-
vation that siRNA-mediated silencing of BAGs or chemical dis-
ruption of BAG interactions using JG-98, an Hsp70 allosteric
regulator45, can correct the trafficking defect associated with
multiple NPC1 disease-causing variants11. Moreover, we found
that SAHA treatment results in a significant reduction of
HDAC7, a principle HDAC that mediates correction of NPC141,
as well as other protein misfolding diseases such as cystic
fibrosis38,46 and alpha-1 antitrypsin deficiency39,40,47.
SCV relationships driving clinical presentation of disease. To
understand the role of epigenetic-sensitive SCV relationships
defined by our bench-based experimental measurements to those
observed in the clinic, we correlated the variant TrIdx value based
on acquisition of Endo HR with the natural history of 27 NPC1
patients that overlap with the input variant dataset (Supple-
mentary Fig. 8; Supplementary Table 3). While there is no sig-
nificant correlation between trafficking and severity or age-
adjusted severity of disease presentation by all NPC1 patients
(Supplementary Fig. 8a, b), we found that class III variants con-
taining patients have a significant correlation with a late age of
neurological onset (ANO) when compared with all other patients
(Supplementary Fig. 8c, middle panel). To map these epigenetic-
sensitive SCV relationships that direct ANO, we used the TrIdx as
the y-axis coordinate to predict the phenotype landscape for the
ANO (z-axis) (Fig. 6a; Supplementary Fig. 8d). Strikingly, we
found in the ANO-phenotype landscape a prominent region
defined by a SCV cluster in CLD5 with class III TrIdx properties
that shows a significant late ANO (Fig. 6a, b, dashed oval, cyan-
blue), likely due to the ability of these residues to maintain a
higher ratio (TrIdx) of post-ER functional protein. The known
variants that contributed to this predicted age-dependent SCV
cluster (V950M, S954L, P1007A, and T1036M) are highly
responsive to SAHA treatment. These results illustrate how VSP
can be used to quantitate SCV set-point tolerance on a residue-
by-residue basis to predict strong candidates for clinical trials
(Fig. 6c, ~70% percentile). Moreover, because SAHA also
improves nearly all class II CLD5 variants to a class III phenotype
with the resultant improvement in cholesterol management
(Fig. 6d, arrow), VSP predicts that improving even class II CLD5
variants (e.g., I1061T) to a class III trafficking by a folding cor-
rector, as has been found for CFTR48, through either a small
molecule chemical chaperone or a proteostasis interventional
strategy, may significantly reduce disease progression and reduce
the impact of disease in early onset patients.
Discussion
We have proposed1 that natural variants distributed across the
world-wide population comprise a library of evolutionary tuned
information that can be used through GPR-ML based SCV to
define the functional properties of the protein fold crucial for
human health. We have now shown that epigenetic modulation of
NPC1 variants reveal distinct regions of SCV relationships that
clearly separate residues involved in trafficking from those
responsible for cholesterol homeostasis in downstream LE/Ly.
SCV relationships revealed that CLD5 is likely a pivotal module
where it forms a biological handshake with MLD3 to direct
trafficking from the ER. Given that residues in the STMD4-
CTMD6 module have less impact on trafficking from the ER, the
genome based phenotype landscapes and corresponding func-
tional structures lead us to suggest that the CLD5 may largely
contribute to the organization of residues in the transmembrane
spanning STMD4-CTMD6 modules to serve as a tunnel to
Fig. 3 Chol-phenotype landscape and Chol-structure in the absence and presence of SAHA. a NPC1 variants are positioned by their variant sequence
position (VarSeqP) (x-axis) normalized to the full-length sequence and the measured TrIdx values of NPC1 variants (y-axis) in the absence (left panel) or
presence (right panel) of SAHA. The projected z-axis (color gradient) is defined by the measured Chol of each variant normalized to I1061T. The spatial
relationships of pairwise comparisons of variants are illustrated as black lines. b The molecular variogram illustrating the spatial variance of measured Chol
for distance values defined by VarSeqP and TrIdx in the absence (black line) or presence (red line) of SAHA (see Methods; Supplementary Fig. 7a). c The
VSP predicted Chol-phenotype landscape is shown as a heatmap in the absence (left panel) or presence (right panel) of SAHA. Confidence relationships
(see Supplementary Fig. 7b) within the molecular variogram range are plotted as contour lines with the top 25% confidence quartile shown as a bold line in
control condition (left panel) and top 5% confidence level shown as bold in SAHA condition (right panel). Color-scale values: severe Chol accumulation
(red); WT Chol accumulation (green). I1061T ER-restricted variant is bolded. Dashed ovals 3 and 4 highlight two SCV clusters defined by the top 25%
quartile that have good TrIdx but defective Chol. dMapping the Chol-phenotype landscape on the NPC1 structure25,29. The highest confident prediction of
the Chol value and the corresponding TrIdx value is assigned for each residue with ball color representing Chol, ball size representing TrIdx, and
transparency representing prediction confidence. SCV clusters 3 and 4 are selectively highlighted as balls in cartoon presentation of the structure. The
proposed cholesterol flow path is shown in gray arrow. e Transmembrane region is shown in side view as cylinders (upper panel) or in top view as loops
(lower panel) colored by predicted Chol value. Transmembrane helices 1–13 are labeled. The variants in SCV clusters 3 and 4 are labeled and shown in
spheres (upper panel) or with C-alpha shown in balls (lower panel)
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Fig. 4 The SAHA responsive structures for TrIdx and Chol. NPC1 structure is colored by the predicted delta value of TrIdx (a, b) or delta value of Chol (c, d)
in response to SAHA. Color-scale values: impair of TrIdx or Chol homeostasis (red-orange), no change (yellow), improve of TrIdx or Chol homeostasis
(cyan-blue). In the right panel of (a) and (c), regions with delta value < 0.2 are shown in gray to highlight the regions corrected by HDACi (i.e., delta value >
0.2). Transmembrane helices 1–13 are labeled in panels (b) and (d). Variants critical for predicted cholesterol flow path are highlighted and labeled in panels
(b) and (d)
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channel the transfer of cholesterol from SNLD1 through the
bilayer following transfer to the LE/Ly25,27,49. A molecular tunnel
channeling cholesterol is supported by recent cryo-EM structures
of a NPC1 homologous protein, Hedgehog Receptor Patched50–53
and a molecular dynamics simulation study of NPC154.
Strikingly, many variants contributing to NPC1 disease do not
exhibit severe trafficking defects yet are critical for function in
downstream LE/Ly, consistent with the notion that export from
the ER is not about quality control—rather about governing the
SCV tolerance value of a set-point assign to each residue in the
fold that we now show can be sensitive to epigenetic control. This
conclusion is consistent with the many observations that ~30% of
regions contributing to the protein fold are not rigidly ordered,
rather are highly dynamic in design, in many cases requiring a
cyclic interaction with multiple downstream partners or ligands
binding of cholesterol in an acidic LE/Ly in the case NPC1, to
achieve function. Mechanistically, we suggest that GPR-ML
reveals the potential for amino acid residues in the polypeptide
chain to individually or as a collective, contribute to fold man-
agement for function through a weighted epigenetic-sensitive
SCV matrix that can be discovered using GPR-ML1. This matrix
response is likely sensitive to proteostasis buffering folding
pathways, to UPS or autophagic pathways promoting
degradation55, or to HSR management of post-ER stability and
function reflecting each residue’s role in NPC1 function.
Mechanistically, whether HDACi sensitive events are due to
direct alteration of the acetylation balance of Lys residues in the
NPC1 polypeptide chain41,56, more indirectly through tran-
scriptional and/or post-translational mechanisms affecting
HDAC-sensitive proteostasis pathways as shown herein24,43,57,58,
and/or other HDAC-sensitive events facilitating endomembrane
trafficking (ER-Golgi-LE/Ly) compartment function24,59, remains
to be determined. Recent controversial results60–64 of HDACi
effects in mouse models emphasize the need for use of the human
genome sequence and patient related models as captured herein,
to point the way1, particularly in response to epigenetic mod-
ifications that are sensitive to the evolutionary trajectory and the
local environment. Consistent with this prediction, from a natural
history perspective, we have shown that epigenetic-sensitive SCV
relationships can predict residues that are more likely to be
responsive to HDACi in human clinical disease.
The sensitivity of SCV relationships dictating the NPC1 fold in
disease to HDAC is generalizable given that HDACi correct a broad
range of misfolding disorders that are triggered by genetic variation
in the population, including cystic fibrosis38, alpha-1-antitypsin
deficiency39,40,47, Gaucher’s disease65, and neurodegenerative
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Fig. 5 Hyperacetylation of NPC1 and proteostasis impact by SAHA. a SAHA leads hyperacetylation of both WT and I1061T-NPC1. Cell lysate of WT or
I1061T/I1061T patient fibroblast was immunoprecipitated by acetylated-lysine (AcK) antibody and then recognized by NPC1 antibody through western
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used as Western blot loading control. Data is presented as fold change to DMSO treatment (mean ± s.d., n= 3). P-values are indicated using student’s two
tailed t-test (*p < 0.05, **p<0.01, ***p<0.001)
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aggregation-driven diseases including Friederich Ataxis66, Alzhei-
mer’s, Parkinson’s, and Huntington67,68. The striking decrease in
the stringency of SCV relationships seen in the molecular var-
iogram linking a variant to restoration of trafficking or function
in response to HDACi now highlights a general role of acetyla-
tion/deacetylation balance in managing plasticity in the sequence-
to-function-to-structure design paradigm revealed by GPR-ML1.
We posit that placement of acetylation prone Lys residues in the
genomic sequence has evolved in conjunction HDAC to dyna-
mically manage plasticity in the context of the local environment,
an interpretation consistent with the observation that the plasti-
city of stem cell fate69–71 and tumorigenesis72, and aging6,7,73,74
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are controlled by the histone deacetylase activity. As such, VSP
provides us with an quantitative platform to not only mechan-
istically understand the impact of genetic variation on function
and structure1, but as shown herein, its epigenetic plasticity. The
striking remodeling effect of HDACi on SCV relationships link-
ing genomics to phenomics in the NPC1 disease population
reveals a potential role for the acetylation sensitive epigenome
and epiproteome to (re)tune global flow of information from the
genome to the functional proteome (Fig. 6e). We have previously
proposed1 that information flow through central dogma can be
best captured by changing our current linear (DNA→ RNA→
Protein) perspective to a SCV-based matrix view (Fig. 6e, SCV
[DNA|RNA|Protein] where the vertical lines are defined by GPR-
ML matrices that capture the SCV-based information flow
through central dogma that generates biology. We now suggest
that GPR-ML describes the epigenetic-sensitive SCV matrices
(Fig. 6e, epi-SCV[DNA|RNA|Protein]) to reveal the environment
sensitive complexity in the individual that make each of us who
we are in health and disease1 over a lifespan (Fig. 6e).
Methods
Reagents. Modified Eagle’s medium (MEM), fetal bovine serum (FBS), penicillin-
streptomycin (P/S), and geneticin (G418) were purchased from Invitrogen Life
Technologies Corporation (Carlsbad, CA). Effectene Transfection Reagent Kit and
DNA purification kit were purchased from QIAGEN Inc. (Valencia, CA). Histone
deacetylase inhibitors (SAHA) were purchased from Cayman Chemical Co. SAHA
was stocked at 5 mM in DMSO and stored at −20 °C. Endoglycosidase H was
purchased from New England BioLabs. A rat monoclonal anti-hNPC1 antibody
was developed against the C-terminal peptide (amino acids 1261–1278). Other
antibodies used in the study are acetylated-lysine (AcK) antibody (AB193, Abcam),
HDAC7 (Ab12174, Abcam), HSF1 (Ab52757, Abcam), HSF1 phosphorylated
(Ab76076, Abcam), Bag1 (3.10G3E2, Santa Cruz Biotechnoligy), Bag2 (Ab79406,
Abcam), Bag3 (Ab5898, Abcam), and GAPDH (AM4300, Invitrogen). All other
chemicals were purchased from Sigma Chemical (St. Louis, MO).
Human fibroblast cells. Human NPC1 fibroblasts were obtained from Coriell
Institute (Camden, NJ) (Supplementary Table 1). All human skin fibroblasts were
maintained in modified Eagle medium containing FBS.
Stable silencing of NPC1. NPC1-deficient stable HeLa-shNPC1 and U2OS-
shNPC1 cells were generated by silencing the endogenous npc1 gene with 3′-UTR
shNPC1 lentivirus. Mission shRNA clone was purchased from Sigma against 3′
UTR (TRCN000000542) of human NPC1 (pLKO-shNPC1) for knockdown of
npc1 gene in human cell lines. Stable clones of npc1-deficient cells were selected
with 5 μg/ml puromycin for 3 weeks. Stable HeLa-shNPC1 cells were cultured in
DMEM medium supplemented with 10% FBS and 5 μg/ml puromycin. Stable
U2OS-shNPC1 cells were cultured in McCoy’s 5A medium supplemented with
10% FBS, 50-units/ml penicillin, 50 μg/ml streptomycin, 5 μg/ml puromycin, and 1
mg/ml G418.
NPC1 variant transient expression vectors. cDNA encoding human
ΔU3hNPC1-WT construct was kindly provided by Dan Ory (Washington Uni-
versity, St Louis, MO). The NPC1 gene was subcloned into bicistronic retroviral
plasmid, pMIEG3 using EcoR1 and Not1 restriction enzyme sites. pMIEG3 vector
was generated from pMSCVneo vector (Clontech) in which the murine phos-
phoglycerate kinase (PKG) promoter and the Neomycin resistance (Neor) genes
were replaced by IRES (Internal Ribosome Entry Site) and EGFP (enhanced green
fluorescent protein) genes. ΔU3hNPC1-WT construct has four substitutions
compared with a standard reference NPC1 sequence (NM_000271.4, Uniprot ID:
O15118), so this WT sequence is named as WT-V21. The substitutions are 387T>C
(Y129Y), 1415T>C (L472P), 1925T>C (M642T), and 2587T>C (S863P).
ΔU3hNPC1-WT has been used as a WT construct in precious publications21,75. It
was derived from pSV-SPORT/NPC1 that has been used as the WT control protein
in previous publications56,76,77. The site-mutagenesis was generated by Quick-
Change XL Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA) using pMIEG3-
NPC1 as template, and all the variants used in this study contain the four back-
ground variants derived from human ΔU3hNPC1-WT (i.e., WT-V) construct.
Endoglycosidase H (Endo H) assay. In Hela cells, NPC1 variants were transiently
expressed for 72 h using Fugene transfection reagents. Cells were washed with 1×
PBS twice and lysed the cells with RIPA lysis buffer (10 mM Tris pH 8.0, 140 mM
NaCl, 1% NP-40, 0.1% sodium-deoxycholate, 0.1% SDS, 1× protease inhibitor
cocktail (PIC), 1 mM PMSF) on ice for 30 min. Cell lysates were obtained by
16,000 × g centrifugation at 4 °C. Protein concentration was measured using the
standard BCA assay. Around ~300–500 mg of cell lysates were incubated with 1–2
mg of rabbit polyclonal anti-NPC1 antibody or rat monoclonal anti-NPC1 anti-
body for overnight at 4 °C. In total, 20–30 μl of protein A/G-Sepharose or Gam-
maBind G-Sepharose beads (GE Healthcare) were added to the cell lysates to
capture the antibody-bound NPC1 for 1 h at 4 °C. Beads were washed with RIPA
lysis buffer 3× with final wash with 1× PBS. Immunoprecipitated NPC1 was eluded
with 1× denaturation buffer (0.5% SDS, 40 mM DTT) at 95 °C for 10 min. Eluted
NPC1 was divided into equal parts and incubated with absence (−) or absence (+)
of 1000 units Endo H enzyme for overnight at 37 °C. Endo H digested samples
were subjected to 4–12% Bis-Tris gradient (Invitrogen) or 4–20% gradient (Bio-
Rad) SDS-PAGE and immunoblotted with rat monoclonal anti-NPC1 antibody
(1:3000). Endo H sensitive (Endo HS) and Endo H resistant (Endo HR) were
identified by their unique migration on SDS-PAGE gels. In U2OS cells, cells were
seeded at 2.0 × 105 cells/ml in 12-well plates and incubated overnight. Transfections
were performed using the reagent FuGENE6 from PROMEGA (Madison, WI) with
a 1:4 ratio, 2 μg DNA:8 μL FuGENE6 in Opti-MEM (1×)+Hepes+ sodium
bicarbonate+ L-glutamine+ 5% FBS. Samples were then incubated for 5 h at 37 °C
and the medium was replaced with normal growth medium. Cells were then
incubated for another 48 h and visualized under the fluorescent microscope for
GFP-positive transfected cells. These variants were all transiently expressed in the
U2OS-SRA-shNPC1 cells. After 72 h from initial plating, cells were lysed with
50 μL/well of 1× RIPA (150 mM NaCl, 1.0% IGEPAL Ca-360, 0.5% Na-deoxy-
chlorate, 0.1% SDS, 50 mM Tris pH 8.0, 1× protease inhibitors, 1× benzonase) on
ice for 30 min. Samples were collected and incubated at 37 °C for 20 min, cen-
trifuged at 20,817 × g at 4 °C for 20 min. Supernatant was collected and the BCA
assay performed. Endo H was performed by addition of 1× glycoprotein denaturing
buffer (New England Biolabs) to 20 μg of lysate and incubated at 50 °C for 30 min.
For each sample, 10,000 U/ml Endo H and 1× Glycobuffer (New England Biolabs)
were added and incubated overnight at 37 °C. Protein samples were separated on
4–12% Bis-Tris BOLT protein gel (Invitrogen) and transferred to nitrocellulose
membrane. Membranes were probed with NPC1 1:1000 and tubulin 1:25,000
diluted in 5% milk solution.
SAHA treatment on NPC1 variants. Human NPC1 variants were transiently
expressed in HeLa-shNPC1 cells. After 24 h posttransfection, cells were treated
with control DMSO or 10 μM SAHA for 72 h. Cell lysates were processed and Endo
H treatment of the NPC1 variants were performed as described above.
Probing proteostasis components in response to SAHA. Patient I1061T/I1061T
fibroblasts were seeded in a 6-well plate and grown until confluent. Once confluent,
cells were treated with DMSO or SAHA at 10 μM for 48 h at 37 °C in normal
growth media. Cells were then washed twice with 1× PBS and then lysed with
75 μL/well of 1× RIPA (150 mM NaCl, 1.0% IGEPAL Ca-360, 0.5% Na-deoxy-
chlorate, 0.1% SDS, 50 mM Tris pH 8.0, 1× protease inhibitors, 1× benzonase) on
ice for 30 min. Samples were collected and then incubated at 37 °C for 20 min.
Samples were then centrifuged at 20,817 × g at 4 °C for 20 min. Supernatant was
Fig. 6 VSP links bench to bedside. a 19 variants from 27 patients with natural history information (Supplementary Table 3) are used as input value for VSP
to generate the ANO-phenotype landscape that uses variant position information (x-axis) and cell-based TrIdx measurement (y-axis) to predict the ANO in
the clinic (z-axis, color scale). The SCV cluster with late ANO (cyan-blue) in top 25% quartile of prediction confidence is highlighted by dashed oval. b The
predicted ANO with highest confidence for each residue is mapped on the structure with the color code the same as panel (a). Variants with late ANO are
shown in balls and labeled. c Distribution of the delta value of cholesterol homeostasis in response to SAHA for all the variants tested21. The variants with
late ANO in the SCV cluster are shown in blue and labeled. d The Chol-phenotype landscape of CLD5 (Fig. 3c, asterisks) are shown with the TrIdx classes
highlighted by dash lines. Black arrow indicates the TrIdx and Chol shift of class II CLD5 variants to class III in response to SAHA. e HDACi remodels the
SCV relationships to manage genotype to phenotype transformation. Addition of HDACi to the same collection of variants from NPC1 population creates a
new SCV matrix linking genotype to phenotype. VSP captures the impact of these epigenetic changes through SCV matrices to interpret and predict the
dynamics of protein fold for its function in the context of local epigenetic environment. The epigenetic modulation of SCV (epi-SCV in the figure) provides a
quantitative platform to characterize the ability of the environment to manage the information flow through central dogma (epi-SCV[DNA|RNA|Protein])
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collected and BCA assay was performed. Once samples were prepared, 40 μg of
total protein was separated on a 10% SDS-PAGE. Proteins were transferred to
nitrocellulose and probed with antibodies of HSF1 (1:10,000 dilution), HSF1
phosphorylated (1:5000 dilution), Bag1 (1:1000 dilution), Bag2 (1:1000 dilution),
and Bag3 (1:1000 dilution), and HDAC7 (1:1000 dilution). GAPDH is probed by
GAPDH antibody (1:100,000 dilution) as loading control. Each was further probed
with their specific secondary antibodies and detected by chemiluminescence.
Natural history analysis. NPC1 subjects were evaluated at the National Institutes
of Health Clinical Center in Bethesda, Maryland in an observational/natural history
protocol (NCT00344331; https://clinicaltrials.gov/ct2/show/NCT00344331?
term=niemann+pick&rank=11). This study was approved by the Eunice Kennedy
Shriver National Institute of Child Health and Human Development Institutional
Review Board. Written consent, and when feasible assent, were obtained. Clinical
information related to disease onset was collected from guardians and record
review. Neurological severity scores were determined by clinical evaluation of nine
major and eight minor clinical areas, such as eye movement, ambulation, speech,
swallow, fine motor skills, cognition, hearing, memory, seizures and so on78. Age-
adjusted severity scores were determined by dividing the neurological severity
scores by the age of the subject at the time of evaluation. The age of neurologic
onset of each variant is calculated by averaging the age of neurologic onset of the
patients (Supplementary Table 3) who contain that variant.
VSP methods. VSP uses a biological adaptation of the general principles of
geostatistics1,9, a well-established Gaussian-process regression (GPR)-based
machine-learning (ML) approach that provides a means to predict the distribution
of a large range of geological, epidemiological, anthropological and environmental
measures in complex geologic landscapes using sparse sampling methods. Below
we described how we apply classical GPR-based ML concepts through VSP to
understand the role of variation in human disease and its application to precision
medicine.
The initial step for VSP is molecular variogram analysis. Assume we have a
variable z (z-axis value) which is positioned by x and y coordinates (x- and y-axis
values) that describe the phenotype landscape. A molecular variogram is first used
to describe how the spatial variance (i.e., the degree of dissimilarity) of z changes
according to the separation distance defined by the x and y coordinates which
enables the calculation of the spatial covariance (SCV) relationships in the dataset.
Suppose the ith (or jth) observation in a dataset consists of a value zi (or zj) at
coordinates xi (or xj) and yi (or yj). The distance h between the ith and jth
observation is calculated by
hði;jÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðxi  xjÞ2 þ ðyi  yjÞ2
q
ð1Þ
and the γ(h)-variance for a given distance (h) is defined by
γ hð Þ ¼ 1
2
ðzi  zjÞ2 ð2Þ
γ(h)-variance is the semivariance of z value between the two observations, which is
also the whole variance of z value for one observation at the given separation
distance h. Here in the paper, we refer γ(h)-variance as spatial variance as indicated
in the y-axis of molecular variogram (main text Figs. 2b and 3b). By Eqs. (1) and
(2), the distance (h) and γ(h)-variance for all the data pairs are generated. Then, the
average values of γ(h)-variance for different distance intervals are calculated to plot
γ(h) versus h used in the molecular variogram. The distance where the model first
flattens out is known as the range. Sample locations separated by distances closer
than the range are spatially correlated, whereas locations farther apart than the
range are not. The spatial covariance (SCV) at the distance (h) is calculated by C
(h)= C(0)− γ(h), where C(0) is the covariance at zero distance representing the
global variance of the data points under consideration (i.e., the plateau of the
variogram).
GPR-based ML is an interpolation/regression method providing optimal
unbiased prediction based on the modeled SCV relationships generated by the
molecular variogram9. In our study, we used a GPR-based regression approach
referred to as ordinary Kriging that has the least assumptions and is the form most
commonly used79. Essentially, SCV can predict the unknown value by local
weighted averaging the surrounding known values, where the weight associated
with the known value is determined according to their positions both in relation to
the unknown point and to one another.
According to variogram, observations within close distance are usually highly
correlated and have more weight for prediction. To solve the optimum and
unbiased weights of SCV relationships, molecular geostatistics aims to minimize
the variance associated with the prediction of the unknown value at location u,
which is generated according to the expression
σ2u ¼ E zu  zu
 2
h i
¼
X
n
i¼1
X
n
j¼1
ωiωjCi;j  2
X
n
i¼1
ωiCi;u þ Cu;u ð3Þ
where zu is the prediction value while zu is the true but unknown value, Ci,j and Ci,u
are SCV between data points i and j, and data points i and u, respectively, and Cu,u
is the SCV within location u. ωi is the weight for data point i. The SCV is obtained
from the above molecular variogram analysis. To ensure an unbiased result, the
sum of weight is set as one.
X
n
i¼1
ωi ¼ 1 ð4Þ
Equations (3) and (4) not only solved the set of weights associated with input
observations, but also provided the minimized ‘molecular Kriging variance’ at
location u which can be expressed as
σ2u ¼ Cu;u 
X
n
i¼1
ωiCi;u þ μ
 !
ð5Þ
where Cu,u is the SCV within location u, ωi is the weight for data point i, and Ci,u
are SCV between data points i and u. µ is the Lagrange Parameter that is used to
convert the constrained minimization problem in Eq. (3) into an unconstrained
one. The resulting minimized Kriging variance provides a weighted SCV score that
represents the confidence for using the SCV relationships both within the input
data points and in relation to the unknown locations. The confidence level is tightly
linked with the distance range in the variogram. The shorter distance between the
unknown point to the input data points, the higher confidence for using the SCV
relationships for prediction.
With the solved weights W, we can calculate the prediction of all unknown
values to generate the complete phenotype landscape by the equation
zu ¼
X
n
i¼1
ωizi ð6Þ
where zu is the prediction value for the unknown data point u, ωi is the weight for
the known data point, and zi is the measured value for data point i 9.
The parameters, for example, range and sill (i.e., plateau) of the variogram in
this study are indicated in Fig. 2b and Fig. 3b, respectively. They were chosen by
minimizing the residual sums of squares of the fitting. Spherical model was chosen
for variogram modeling because it yielded the best leave-one-out cross-validation
result for the datasets when compared with linear, exponential and gaussian
models. In the final prediction, for each unknown position, minimal 5 nearby
variants and maximal 19–25 nearby variants were included in the weighted
averaging calculation (i.e., Eq. (6)). All the procedures were performed in the
ordinary Kriging module in GS+, version 10 from gammadesign software (https://
geostatistics.com/). We also tried the ordinary Kriging module in gstat package80,
which gave identical results. The source code for running gstat package in R is
uploaded to https://doi.org/10.17632/ycw667nv5f.1 (see Code availability). The
multivariate linear regression and random forest regression were performed in R by
using basic lm function or randomForest package, respectively.
We used leave-one-out and k-fold cross-validation to assess the performance of
VSP strategy. In the leave-one-out cross-validation all data are initially used to
build the molecular variogram and Kriging models. Then, we remove each data
point, one at a time and use the rest of the data points to predict the missing value.
We repeat the prediction for all data points and compare the prediction results
with the measured value to generate the Pearson’s r-value and its associated p-value
(ANOVA test). For the k-fold cross-validation, samples are randomly partitioned
into k= 48, 24, 12, 8, 4, 3, or 2 sets. Of the k sets, a single set is used as validation
data and the remaining k-1 sets are used as training data. The size of training and
validation subsamples are indicated for each k-fold in the figures. The cross-
validation process is repeated k times and every set is used as validation once. The
prediction of each sample is collected. For k < 48, the partition process is repeated
five times and the averaged Pearson’s r- and p-value of the correlation between
predicted value and actual value is reported. The error bars associated with each
prediction is the prediction confidence. In the correlation analyses, we took the
confidence level into account as weight. A prediction with small uncertainty will
have a larger weight because it is more precise than prediction with larger
uncertainty. The weight is calculated as: ωi ¼ 1σ2i , where σ
2
i is the variance for i.
Quantitative correlation analyses and p-value calculations were performed using
the software Originpro 2016 or R. A p-value < 0.05 was considered to indicate
statistical significance.
Phenotype landscapes predicted based on a sparse collection of variants contain
experimental information that comprises the full range of values on function y- and
z-axis for the entire polypeptide sequence (x-axis). To map the function predictions
onto structure, we assign the prediction value with highest confidence to each
residue to generate a functional structure that illustrates all values interpolated
from the sparse collection variants used to generate the phenotype landscape
displaying at atomic resolution. PDB:3JD8 and PDB: 5U73 are used for
NPC1 structure maping25,29. All the structural presentations were produced by the
software of PyMOL.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Code availability
We included a demo input data, the R-codes for generating phenotype landscape and
instructions as a Zip file named “ExampleCode.Zip”, which is uploaded to https://doi.
org/10.17632/ycw667nv5f.1. Additional modified scripts can be accessed upon request.
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Data availability
The source data underlying Figs. 1–4 are provided as Source Data file. The uncropped
blots of Fig. 5b are shown in Supplementary Fig. 9. The patients data in Fig. 6a, b are
provided as Supplementary Table 3. The output phenotype landscapes for Figs. 2c, 3c
and 6a are uploaded as output files in https://doi.org/10.17632/ycw667nv5f.1. All other
relevant data are available from the corresponding author on request.
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